CRNXCrinetics Pharmaceuticals Inc

NAS · US · Healthcare · Biotechnology · crinetics.com

84.69USD0.00%Mkt Cap: 8.99B $P/E: —3d ago

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The c…

Headline	Source	Time
Older
Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired revenue of US$25.12 million with a net loss of US$120.86 million and a basic loss per share of US$1.14. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' share price has risen strongly over the past year, with a 30 day share price return of 98.34% and a 1 year total shareholder return of 186.46%, reflecting rising expectations after the Vertex acquisition...	Simply Wall St.	Aug 4
Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength	MMT Newswires	Aug 4
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.	Zacks	Aug 4
Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call	Moby	Aug 4
Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...	Simply Wall St.	Aug 4
Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...	Simply Wall St.	Aug 4
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +7.32% and +69.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?	Zacks	Aug 3
Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.	Investor's Business Daily	Aug 3
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target There are other reasons to pay attention to Viking Therapeutics.	Motley Fool	Jul 31
Vertex was sole bidder in high-premium Crinetics acquisition Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.	BioPharma Dive	Jul 22
Biotech IPO Gains Crush AI Listings With Standout 55% Return (Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam	Bloomberg	Jul 21
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]	IInsider Monkey	Jul 15
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.	Motley Fool	Jul 14
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? Vertex Pharmaceuticals recently announced its largest-ever acquisition.	Motley Fool	Jul 13
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse	MarketBeat	Jul 11
Why This Pharmaceutical Stock Jumped Close to 100% This Week	Motley Fool	Jul 10
Why Crinetics Stock Soared 99% This Week	24/7 Wall St.	Jul 9
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says	MMT Newswires	Jul 8
Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?	IInsider Monkey	Jul 8
Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal	Simply Wall St.	Jul 8
Vertex’s Crinetics Deal Balances Growth with Integration Risk	MarketBeat	Jul 8
Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now?	Simply Wall St.	Jul 8
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal	Simply Wall St.	Jul 8
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.	Motley Fool	Jul 8
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?	Zacks	Jul 8
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?	Stocktwits	Jul 8
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?	Stocktwits	Jul 8
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.	Motley Fool	Jul 8
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout	BeInCrypto	Jul 8
Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology	Simply Wall St.	Jul 7
Sector Update: Healthcare Stocks Gain Late Afternoon	MMT Newswires	Jul 7
Vertex Pays $10 Billion to Enter Rare Endocrine Disease	GuruFocus.com	Jul 7
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal	Barrons.com	Jul 7
Top Midday Gainers	MMT Newswires	Jul 7
CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition	Stocktwits	Jul 7
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles	Investor's Business Daily	Jul 6
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion	The Wall Street Journal	Jul 6
Crinetics soars on $10B acquisition by Vertex	Investing.com	Jul 6
Vertex to buy Crinetics for $10 billion to expand rare-disease business	Reuters	Jul 6
Sector Update: Healthcare Stocks Gain Late Afternoon	MMT Newswires	Jul 2
Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock Positioned for Growth After Promising Atumelnant Clinical Results?	IInsider Monkey	Jun 30
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree	24/7 Wall St.	Jun 25
Leerink Upholds Outperform Rating for Crinetics Pharmaceuticals (CRNX)	IInsider Monkey	Jun 17
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why	IInsider Monkey	Jun 11
A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026	Simply Wall St.	Jun 4
What Do Analysts Say About Crinetics Pharmaceuticals (CRNX)?	IInsider Monkey	May 29

CRNXCrinetics Pharmaceuticals Inc

Industry Peers